Fidelity SPDR Advertisement
Home > Boards > Free Zone > User's Groups > Mohacsy's Safe Portfolio Member Forum

Orphan Drug Status doesn't assure FDA approval of

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
n4807g Member Profile
Member Level 
Followed By 30
Posts 27,179
Boards Moderated 0
Alias Born 07/08/03
160x600 placeholder
U.S. Stocks Wither; S&P 500 Ends 4-day Win Steak
The S&P 500 snapped a four-day winning streak after modest early-morning gains faded, leaving U.S.stock averages in the red on Wednesday.
Top Equities Stories Of The Day
Hong Kong Protests Expose Differences in Local Media
FTSE 100 Climbs As Oil Stocks Advance
Correction to AT&T Earnings Preview Story
Airbus 'Actively Discussing' New A321neo With Airlines -Reuters
Stifel Financial to Hire Two Former Merrill Lynch Advisers
U.S. Stocks Gain, but IBM Weighs on Dow
U.S. Hot Stocks: Hot Stocks to Watch
EU Seeks Trans-Atlantic Air Pact Feedback
n4807g Member Level  Monday, 04/23/12 12:16:00 PM
Re: FullBoogie post# 60301
Post # of 68569 
Orphan Drug Status doesn't assure FDA approval of the compound being evaluated, it confers certain marketing advantages and tax credits should the drug be approved.

Like most small biotechs CYTR will succeed or fail on the technology they employ. In CYTR's case the delivery system. The near term future of INNO-206 will be clear when they report interim findings of their ongoing 2b trial.

Like all biotechs this is a speculative investment, but I've watched many companies with similar strategies do well. The preliminary data look promising (no guarantee) but as I said in my previous post Abraxane uses Albumin as the entry vehicle in tumors and CYTR uses the same concept.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist